Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH 2)

Trial Profile

Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH 2)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Pazopanib (Primary) ; Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Acronyms SWITCH-2
  • Most Recent Events

    • 19 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 19 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 03 Feb 2017 This trial was completed in Austria (End date: 14 Nov 2016) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top